ProCE Banner Activity

Expert Selections From ASH 2020: Myelodysplastic Syndromes and Myeloproliferative Neoplasms

Clinical Thought
In this commentary, 2 experts discuss their top presentation choices at ASH 2020 in MDS and MPNs with the most potential to impact clinical practice.

Released: February 23, 2021

Expiration: February 22, 2022

No longer available for credit.

Share

Faculty

Amy E. DeZern

Amy E. DeZern, MD, MHS

Associate Professor
Oncology and Medicine
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Srdan Verstovsek

Srdan Verstovsek, MD, PhD

Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology

Faculty Disclosure

Primary Author

Amy E. DeZern, MD, MHS

Associate Professor
Oncology and Medicine
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Amy E. DeZern, MD, MHS, has disclosed that she has received consulting fees from Astex, Bristol-Myers Squibb, Gilead Sciences, and Novartis.

Srdan Verstovsek, MD, PhD

Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Srdan Verstovsek, MD, PhD, has disclosed that he has received funds for research support from AbbVie, AstraZeneca, Blueprint, Celgene, CTI BioPharma, Galecto, Genentech, Incyte, Ital Pharma, Kartos, Novartis, Prelude, Protagonist, Promedior, Sierra Oncology, and Telios and consulting fees from Bristol-Myers Squibb, Celgene, Constellation, Disc Medicine, Incyte, Novartis, Pharma Essentia, Protagonist, and Sierra Oncology.